Strategic Vision: A Global Pharma Company
Complex Generics and Biosimilars Opportunity
R&D investments focused toward complex generics and biosimilars
Products in development target US$ 70.7 bn of which complex categories account for ~85%
Launches in key categories like Inhalation and biosimilars
Several filings in each of the key categories underway
Pipeline under development - Market Size Split¹
LUPIN
First biosimilar filed in
the US with several
others under
development
Depot Injectibles
6%
IUD / Implant
1%
Complex injectables including
depot injectables
1. Sales: IQVIA MAT Mar 2022/ Company reported sales
Ophtal/Others
1%
Multiple Complex orals with barriers
to entry under development
Orals
15%
Biosimilars
30%
$70 bn+
market
Inhalation
25%
Injectables
22%
Inhalation pipeline delivery to
accelerate in near term
14View entire presentation